Literature DB >> 7689591

Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy.

A Khalili-Shirazi1, P Atkinson, N Gregson, R A Hughes.   

Abstract

Immunisation with the peripheral nerve myelin proteins P0 or P2 induces inflammatory neuropathy in animals. We sought antibodies with an ELISA to these proteins in 38 patients with acute Guillain-Barré syndrome (GBS), 32 patients with chronic idiopathic demyelinating polyradiculoneuropathy (CIDP), 31 patients with other neuropathies (ONP) and 26 normal control (NC) subjects. We discovered IgM antibodies to human P0 protein in the sera of 18.5% of the patients with GBS, 15.6% with CIDP, 6.4% with ONP and 3.8% of NC subjects. Of the sera which reacted with P0, sera from 4/7 of GBS, 3/5 of CIDP, 1/2 of ONP patients and 0/1 of NC subjects reacted with a synthetic P0 peptide representing residues 150-169 from the cytoplasmic portion of the molecule. IgG antibodies to P0 were slightly less common than IgM antibodies, being present in only 7.9% of GBS, 0% of CIDP and 3% of ONP patients and 0% of NC subjects. We found antibodies to bovine P2 protein more commonly than antibodies to P0. IgM antibodies were present in 39.5% of GBS, 34.4% of CIDP, 16.1% of ONP patients and 15.4% of NC subjects. IgG antibodies were present in 18.4% of GBS, 12.5% of CIDP, 3.2% of ONP patients and 7.6% of NCs. Of the sera which contained antibodies to P2 protein, only a few reacted with P2 peptides 14-25 or 58-81, but without any consistent pattern of reactivity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689591     DOI: 10.1016/0165-5728(93)90255-w

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

Review 1.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy.

Authors:  Hye-Jung Kim; Cha-Gyun Jung; Mark A Jensen; Danuta Dukala; Betty Soliven
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 3.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

4.  The Role of Peripheral Myelin Protein 2 in Remyelination.

Authors:  Mark Stettner; Jennifer Zenker; Fabian Klingler; Fabian Szepanowski; Hans-P Hartung; Anne K Mausberg; Christoph Kleinschnitz; Roman Chrast; Bernd C Kieseier
Journal:  Cell Mol Neurobiol       Date:  2017-04-26       Impact factor: 5.046

5.  T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P A Csurhes; A-A Sullivan; K Green; M P Pender; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

6.  Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a).

Authors:  C M Gabriel; N A Gregson; N W Wood; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

7.  Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy.

Authors:  H R Inglis; P A Csurhes; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-08       Impact factor: 10.154

8.  Structural and functional characterization of human peripheral nervous system myelin protein P2.

Authors:  Viivi Majava; Eugenia Polverini; Alberto Mazzini; Rahul Nanekar; Wiebke Knoll; Judith Peters; Francesca Natali; Peter Baumgärtel; Inari Kursula; Petri Kursula
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

Review 9.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

10.  A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy.

Authors:  Cédric Louvet; Beniwende G Kabre; Dan W Davini; Nicolas Martinier; Maureen A Su; Jason J DeVoss; Wendy L Rosenthal; Mark S Anderson; Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2009-02-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.